You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美新冠疫苗计划首席科学顾问:FDA下月10日开会审批辉瑞疫苗
阿思达克 11-23 10:26
美国政府新冠疫苗计划首席科学顾问Moncef Slaoui表示,美国食品及药物管理局将於12月中批准使用辉瑞(PFE.US)及BioNTech(BNTX.US)研发的新冠疫苗,并开展美国史上最大的疫苗注射计划。美国食品及药物管理局局外顾问将於12月10日开会检视上述疫苗的紧急使用申请,美国医护人员及其他获建议牵先注射疫苗的人士,将在当局批准疫苗後一至两天内获注射疫苗。

Slaoui亦表示,美国七成多人口须接种新疫苗才能达致群体免疫,美国希望明年5月达到有关目标。

辉瑞声称疫苗的有效性达95%。Moderna(MRNA.US)药厂的疫苗料於12月寻求美国当局批准使用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account